Advertisement
Screener

EDITAS MEDICINE, INC. (EDIT) Other Comprehensive Income (Loss), Net of Tax

2.1 / 5 stars · 37/88 Roast Me

EDITAS MEDICINE, INC. Other Comprehensive Income (Loss), Net of Tax

EDITAS MEDICINE, INC. (EDIT) reported Other Comprehensive Income (Loss), Net of Tax of -$6.00 thousand for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-02.

Discontinued › Income Statement

us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2023-08-02

  • EDITAS MEDICINE, INC. other comprehensive income (loss), net of tax for the quarter ending 2023-06-30 was -$6.00K.
  • EDITAS MEDICINE, INC. other comprehensive income (loss), net of tax for the quarter ending 2023-03-31 was $1.32M.
  • EDITAS MEDICINE, INC. other comprehensive income (loss), net of tax for the quarter ending 2022-09-30 was -$904.00K, a 13014.29% decline year-over-year.
  • EDITAS MEDICINE, INC. other comprehensive income (loss), net of tax for the quarter ending 2022-06-30 was -$878.00K, a 44000.00% decline year-over-year.
  • EDITAS MEDICINE, INC. other comprehensive income (loss), net of tax for fiscal 2022 was -$3.11M.
  • EDITAS MEDICINE, INC. other comprehensive income (loss), net of tax for fiscal 2021 was -$447.00K.
  • EDITAS MEDICINE, INC. other comprehensive income (loss), net of tax for fiscal 2020 was -$153.00K, a 212.50% decline from fiscal 2019.
  • EDITAS MEDICINE, INC. other comprehensive income (loss), net of tax for fiscal 2019 was $136.00K, a 189.36% increase from fiscal 2018.
Period endOther Comprehensive Income (Loss), Net of Tax 3 monthOther Comprehensive Income (Loss), Net of Tax 6 monthOther Comprehensive Income (Loss), Net of Tax 9 monthOther Comprehensive Income (Loss), Net of Tax 12 month
2023-06-30-$6.00K
10-Q · filed 2023-08-02
$1.32M
derived: sum of 2 quarters · filed 2023-08-02
2023-03-31$1.32M
10-Q · filed 2023-08-02
2022-12-31-$3.11M
10-K · filed 2023-02-22
2022-09-30-$904.00K
10-Q · filed 2022-11-02
-$1.78M
derived: sum of 2 quarters · filed 2023-08-02
-$3.80M
derived: sum of 3 quarters · filed 2023-08-02
2022-06-30-$878.00K
10-Q · filed 2023-08-02
-$2.89M
derived: sum of 2 quarters · filed 2023-08-02
2022-03-31-$2.02M
10-Q · filed 2023-08-02
2021-12-31-$447.00K
10-K · filed 2023-02-22
2021-09-30$7.00K
10-Q · filed 2022-11-02
$9.00K
derived: sum of 2 quarters · filed 2022-11-02
-$18.00K
derived: sum of 3 quarters · filed 2022-11-02
2021-06-30$2.00K
10-Q · filed 2022-11-02
-$25.00K
derived: sum of 2 quarters · filed 2022-11-02
2021-03-31-$27.00K
10-Q · filed 2022-11-02
2020-12-31-$153.00K
10-K · filed 2023-02-22
2020-09-30-$231.00K
10-Q · filed 2021-11-09
-$742.00K
derived: sum of 2 quarters · filed 2021-11-09
-$155.00K
derived: sum of 3 quarters · filed 2021-11-09
2020-06-30-$511.00K
10-Q · filed 2021-11-09
$76.00K
derived: sum of 2 quarters · filed 2021-11-09
2020-03-31$587.00K
10-Q · filed 2021-11-09
2019-12-31$136.00K
10-K · filed 2022-02-24
2019-09-30-$6.00K
10-Q · filed 2020-11-06
$10.00K
derived: sum of 2 quarters · filed 2020-11-06
$68.00K
derived: sum of 3 quarters · filed 2020-11-06
2019-06-30$16.00K
10-Q · filed 2020-11-06
$74.00K
derived: sum of 2 quarters · filed 2020-11-06
2019-03-31$58.00K
10-Q · filed 2020-11-06
2018-12-31$47.00K
10-K · filed 2021-02-26
2018-09-30-$83.00K
10-Q · filed 2019-11-12
-$30.00K
derived: sum of 2 quarters · filed 2019-11-12
-$6.00K
derived: sum of 3 quarters · filed 2019-11-12
2018-06-30$53.00K
10-Q · filed 2019-11-12
$77.00K
derived: sum of 2 quarters · filed 2019-11-12
2018-03-31$24.00K
10-Q · filed 2019-11-12
2017-12-31-$76.00K
10-K · filed 2020-02-26

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kyverna Therapeutics, Inc. (KYTX)United States$0.434B-3.60
Scribe Therapeutics, Inc. (SCTX)United States$0.410B
Eikon Therapeutics, Inc. (EIKN)United States$0.446B
Zura Bio Ltd (ZURA)$0.398B-6.56
Surrozen, Inc./DE (SRZN)United States$0.395B
AGENUS INC (AGEN)United States$0.383B1.41
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
C4 Therapeutics, Inc. (CCCC)United States$0.373B-5.65
FENNEC PHARMACEUTICALS INC. (FENC)United States$0.371B-115.85
REGENXBIO Inc. (RGNX)United States$0.477B-3.30